Sign in →

Test Code GDCU Gadolinium/Creatinine Ratio, Urine


Specimen Required


Only orderable as part of a profile. For more information see GDUCR / Gadolinium/Creatinine Ratio, Random, Urine.


Useful For

Measurement of gadolinium concentration for assessing chronic exposure and monitoring effectiveness of dialysis using a random urine collection

Method Name

Only orderable as part of a profile. For more information see GDUCR / Gadolinium/Creatinine Ratio, Random, Urine.

 

Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)

Reporting Name

Gadolinium/Creat Ratio, U

Specimen Type

Urine

Specimen Minimum Volume

1.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Urine Refrigerated (preferred) 28 days
  Ambient  28 days
  Frozen  28 days

Reference Values

Only orderable as part of a profile. For more information see GDUCR / Gadolinium/Creatinine Ratio, Random, Urine.

 

0-17 years: Not established

≥18 years: <0.8 mcg/g creatinine

Clinical Reference

1. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007;22(11):3179-3185

2. Christensen KN, Lee CU, Hanley MM, et al. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2011;64(1):91-96

3. Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations. J Am Acad Dermatol. 2011;65(6):1095-1106

4. Telgmann L, Sperling M, Karst U. Determination of gadolinium-based MRI contrast agents in biological and environmental samples: A review. Analytica Chimica Acta. 2013;764:1-16

5. Daftari Besheli L, Aran S, Shaqdan K, et al. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014;69(7):661-668

6. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J. Magn Reson Imaging 2009;30(6):1259-1267

7. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275:772-782

8. Bornhorst J, Wegwerth P, Day P, et al. Urinary reference intervals for gadolinium in individuals without recent exposure to gadolinium-based contrast agents. Clin Chem Lab Med. 2020;58(3):e87-e90. doi: 10.1515/cclm-2019-0607

9. Alwasiyah D, Murphy C, Jannetto P, Hogg M, Beuhler MC. Urinary Gadolinium Levels After Contrast-Enhanced MRI in Individuals with Normal Renal Function: a Pilot Study. J Med Toxicol. 2019;15(2):121-127

Day(s) Performed

Thursday

Report Available

2 to 8 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

83018

LOINC Code Information

Test ID Test Order Name Order LOINC Value
GDCU Gadolinium/Creat Ratio, U 93854-8

 

Result ID Test Result Name Result LOINC Value
615339 Gadolinium/Creat Ratio, U 93854-8